Table 1 Demographic characteristics of study participants categorized by stratified by asymptomatic, mild symptomatic, mild pneumonia, severe and critical Covid-19 cases.

From: Immune transcriptomic analysis on COVID-19 patients with varying clinical presentations identifies severity markers

Characteristic

N

Asymptomatic1

Mild Symptomatic1

Mild Pneumonia1

Severe1

Critical1

p-value2

Number of patients

 

70

41

51

33

33

 

Living status

228

     

< 0.001

Alive

 

70 (35%)

41 (21%)

50 (25%)

28 (14%)

11 (5.5%)

 

Dead

 

0 (0%)

0 (0%)

1 (3.6%)

5 (18%)

22 (79%)

 

Gender

228

     

0.034

Female

39

6 (13%)

8 (21%)

15 (39%)

4 (11%)

6 (16%)

 

Male

189

64 (34%)

33 (17%)

36 (19%)

29 (15%)

27 (14%)

 

Height [m]

130

165 (158–166)

163 (160–166)

167 (163–175)

168 (165–174)

164 (157–172)

0.05

Weight [Kg]

134

72 (59–83)

73 (65–86)

87 (75–94)

80 (73–94)

78 (70–93)

0.013

Body Mass Index (BMI) [kg/m2]

131

26.1 (23.4–27.7)

28.7 (24.0–30.8)

29.1 (27.3–33.0)

27.4 (25.4–31.3)

27.9 (25.3–30.4)

0.031

COVID-19 Average CT

195

22.1 (18.2–28.1)

21.5 (17.8–27.2)

25.6 (20.0–31.6)

27.2 (23.3–33.5)

27.4 (23.4–30.6)

< 0.001

White blood cell (WBC) [x103/uL]

220

6.5 (5.4–7.6)

6.0 (4.8–7.3)

5.7 (4.3–7.9)

9.1 (7.1–11.9)

12.8 (8.7–21.6)

< 0.001

Red blood cell (RBC) [x106/uL]

220

5.20 (4.90–5.40)

5.10 (4.70–5.53)

4.90 (4.50–5.50)

4.10 (3.30–4.70)

3.10 (2.60–3.90)

< 0.001

Neutrophil [%]

199

57 (50–62)

54 (48–63)

59 (53–71)

80 (74–85)

90 (82–93)

< 0.001

Lymphocyte [%]

220

30 (25–37)

34 (28–39)

29 (19–37)

12 (9–15)

6 (4–14)

< 0.001

Monocyte [%]

220

8.8 (7.3–10.9)

9.0 (7.5–12.0)

8.8 (6.5–10.5)

6.6 (3.8–9.3)

4.3 (2.9–6.6)

< 0.001

Eosinophil [%]

219

1.30 (0.40–3.15)

1.10 (0.28–1.83)

0.40 (0.00–1.00)

0.20 (0.00–1.20)

0.20 (0.00–1.30)

< 0.001

Basophil [%]

220

0.40 (0.30–0.60)

0.50 (0.30–0.80)

0.30 (0.20–0.50)

0.30 (0.10–0.50)

0.20 (0.10–0.40)

< 0.001

D-Dimer [mg/L FEU]

129

0.30 (0.25–0.37)

0.50 (0.32–0.95)

0.42 (0.31–0.69)

2.08 (0.86–3.50)

4.57 (2.18–5.88)

< 0.001

Fibrinogen [g/L]

70

6.80 (6.80–6.80)

NA (NA-NA)

4.60 (4.08–4.60)

3.70 (2.93–4.80)

3.50 (2.40–4.40)

0.2

Total Protein [g/L]

190

77 (71–80)

75 (72–78)

69 (66–74)

68 (62–75)

67 (59–74)

< 0.001

Albumin [g/L]

210

42 (38–44)

39 (36–42)

34 (30–37)

25 (21–30)

24 (20–27)

< 0.001

Alkaline phosphatase (ALP) [U/L]

200

81 (69–99)

70 (59–87)

76 (58–95)

99 (74–135)

118 (87–266)

< 0.001

Alanine aminotransferase (ALT) [U/L]

187

25 (18–38)

23 (20–43)

33 (20–55)

48 (28–79)

31 (19–68)

0.027

Glucose [mmol/L]

189

5.10 (4.48–5.90)

5.65 (5.08–6.88)

6.00 (5.25–8.00)

8.30 (6.90–10.10)

9.20 (6.60–11.00)

< 0.001

C-reactive protein (CRP) [mg/L]

219

4 (2–8)

3 (2–10)

21 (5–59)

41 (10–80)

73 (44–157)

< 0.001

Procalcitonin [ng/mL]

88

0.25 (0.14–0.39)

0.09 (0.06–0.14)

0.15 (0.06–0.34)

0.32 (0.13–0.95)

0.59 (0.22–1.89)

< 0.001

Ferritin [ug/L]

125

256 (218–574)

186 (59–331)

520 (139–842)

777 (458-1,482)

1,005 (593-1,898)

< 0.001

Interleukin-6 (IL-6) [pg/mL]

82

NA (NA-NA)

25 (13–40)

22 (9–50)

28 (14–107)

90 (42–180)

0.004

  1. 1Median (25–75%); n (%).
  2. 2Kruskal-Wallis rank sum test; Fisher’s exact test.
Back to article page